From the FDA Drug Label
Following a 15 unit intravenous bolus injection of LYUMJEV in healthy subjects, the geometric mean (CV%) clearance of insulin lispro-aabc was 32 L/hour (22%) and the median half-life of insulin lispro-aabc was 44 minutes.
The half-life of insulin lispro is 44 minutes 1.
From the Research
The half-life of insulin lispro is approximately 1 hour. This rapid-acting insulin analog begins working within 15-30 minutes after injection, reaches peak activity between 30 minutes and 2.5 hours, and has a total duration of action of about 3-5 hours 2. The short half-life of insulin lispro allows it to more closely mimic the body's natural insulin response to meals compared to regular human insulin.
Key Characteristics of Insulin Lispro
- Rapid onset of action: 15-30 minutes after injection
- Peak activity: 30 minutes to 2.5 hours
- Duration of action: approximately 3-5 hours
- Half-life: approximately 1 hour
This pharmacokinetic profile makes insulin lispro ideal for mealtime insulin coverage, as it can be administered immediately before eating (or even just after eating if necessary) 3. The rapid onset and short duration help reduce the risk of delayed hypoglycemia that can occur with longer-acting insulins. For optimal blood glucose management, insulin lispro should be used as part of a regimen that also includes longer-acting insulin to provide basal coverage throughout the day 4.
Clinical Implications
- Insulin lispro is suitable for patients who require flexible mealtime insulin coverage
- It can be used in patients with type 1 or type 2 diabetes who require rapid-acting insulin
- Insulin lispro should be used in conjunction with longer-acting insulin to provide basal coverage throughout the day.